UroGen Pharma, Ltd. announced the appointment of two key executive officers: Ron Bentsur has joined the company as Chief Executive Officer and Gary Titus has joined the company as Chief Financial Officer. In addition, Gil Hakim has been appointed President of Israeli Operations. Ron brings two decades of biopharmaceutical experience to UroGen and a track record of taking clinical stage drug candidates through the FDA approval process.

Mr. Bentsur is an experienced biopharmaceutical CEO and joins UroGen from Keryx Biopharmaceuticals, where he spent six years as Chief Executive Officer. Most recently, Mr. Titus served as the Chief Financial Officer of BioCardia.